Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

por Angelantonio Maglio, Carolina Vitale, Simona Pellegrino, Cecilia Calabrese, Maria D’Amato, Antonio Molino, Corrado Pelaia, Massimo Triggiani, Girolamo Pelaia, Cristiana Stellato, Alessandro Vatrella
Publicado 2021

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

por Giovanna Elisiana Carpagnano, Emanuela Resta, Massimiliano Povero, Corrado Pelaia, Mariella D’Amato, Nunzio Crimi, Nicola Scichilone, Giulia Scioscia, Onofrio Resta, Cecilia Calabrese, Girolamo Pelaia, Maria Pia Foschino Barbaro
Publicado 2021